Maxigen Biotech (TPE:1783) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Maxigen Biotech's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Maxigen Biotech's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Maxigen Biotech LT-Debt-to-Total-Asset Historical Data

The historical data trend for Maxigen Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech LT-Debt-to-Total-Asset Chart

Maxigen Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Maxigen Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Maxigen Biotech LT-Debt-to-Total-Asset Calculation

Maxigen Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	1492.986
	=	0.00

Maxigen Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	1532.947
	=	0.00

Maxigen Biotech (TPE:1783) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Maxigen Biotech LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxigen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333

Website

https://www.mbi.com.tw

Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is mainly engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products. It generates the majority of the revenue from the Biomedical products segment.

Maxigen Biotech Headlines

No Headlines